{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-021990","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.267416+00:00","generated_at":"2026-05-25T02:05:43.035593+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alumis reports positive 52-week Phase 2 OLE data for ESK-001 in plaque psoriasis at AAD 2025","bullets":["ESK-001 40 mg BID achieved PASI 90 61.3%, PASI 100 38.8%, sPGA 0 38.8% at Week 52 (mNRI, n=80).","Responses sustained or improved vs Week 12; 80% of ≥PASI-75 responders at Week 12 maintained or improved at Week 52.","No new safety findings; most TEAEs mild-to-moderate and self-limited.","Phase 3 ONWARD program ongoing; topline data expected Q1 2026.","Patient-reported outcomes: DLQI 0/1 61.3% and itch NRS≤4 81.3% at Week 52."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-021990","json":"https://secwatch.observer/filing/0001104659-25-021990.json","markdown":"https://secwatch.observer/filing/0001104659-25-021990.md","text":"https://secwatch.observer/filing/0001104659-25-021990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/0001104659-25-021990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T02:05:43.035593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}